The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia
Background Comparison between functionality and cognition in elderly patients with Alzheimer’s dementia (AD) and without cognitive impairment with positive and negative Aβ‐42 and p‐Tau biomarkers evaluated using the Luminex technique. Method Patients with Alzheimer’s dementia and normal cognition (c...
Gespeichert in:
| Veröffentlicht in: | Alzheimer's & dementia 2021-12, Vol.17 (S4), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | S4 |
| container_start_page | |
| container_title | Alzheimer's & dementia |
| container_volume | 17 |
| creator | Valu dos Santos, Lorena Aline Burgos, Ivonne Carolina Bolaños Costa, Mônica Vieira de Oliveira Hansen, Erika Dias, Natália Silva da Fonseca, Aristeu Mascarenhas Miranda, Mariana Figueiredo Miranda, Millena Figueiredo Gomes, Giulia Costa de Mattos Viana, Bernardo Bicalho, Maria Aparecida Camargos |
| description | Background
Comparison between functionality and cognition in elderly patients with Alzheimer’s dementia (AD) and without cognitive impairment with positive and negative Aβ‐42 and p‐Tau biomarkers evaluated using the Luminex technique.
Method
Patients with Alzheimer’s dementia and normal cognition (control) were recruited. They were divided in two groups according to their clinical diagnosis: AD group (n=30) and control group (CTRL) (n=10). The AD group was then divided in patients with positive (n=21) and negative (n=9) Aβ‐42 and p‐Tau biomarkers. The participants were submitted to sociodemographic. The general cognition was evaluated through the following instruments: the Mini‐Mental State Examination (MMSE), semantic verbal fluency (SVF), animal fluency, short term memory, and recognition of CERAD battery, and functionality was evaluated by the Pfeffer scale. Samples from the cerebrospinal fluid (CSF) of patients were collected, processed, and stored at ‐80°C until use. The Luminex technique was then used for the Aβ‐42, t‐Tau, p‐Tau, t‐Tau/Aβ‐42 ratio, and p‐Tau/Aβ‐42 ratio biomarker analysis. Obtained data was processed and analyzed through the software SPSS 22.0.
Result
Comparison between control patients and patients with AD, as defined by clinical diagnosis, did not show significant differences regarding to Aβ‐42 expression in CSF (U=91,000; p=0,067), (AD=1119,0360, SD=708,98952 vs CTRL=775,2623 SD=341,67835). However, there was a significant difference between groups concerning t‐Tau protein, (U=198,500; p=0,028), p‐Tau (U=250,00, p=0,001) and p‐Tau/Aβ‐42 ratio (U=238,00; p=0,005). In terms of cognitive variables, all showed significant differences between groups: MMSE (U=46,500, p=0,001), SVF (U=39,000; p |
| doi_str_mv | 10.1002/alz.057838 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_alz_057838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ057838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1138-74081e2b760b403d6b4387eeed23598a740a0bfbe13b6f0979c4d306c882464d3</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EEqWw4QReI1Js589ZRhV_UiU2ZcMmcpJJY0icyE6p2lWPwJYDcAEOwiF6EhwCiBWreZr3zZPmIXRKyYQSwi5EtZkQP-Qu30Mj6vvM8VkY7f_qgByiI2MeCfEIp_4Ivc1LwBoq0clGmVK2WNSNWuD44323ffEYFirHrZVzscSpbGqhn0Cbc1wsVdbfiEp26y8qaxZK9issFW5tIKjO4JXsymbZ_bjPgGXdCqlr6w7hf0kcV5sSZA16t301OIcek-IYHRSiMnDyPcfo_upyPr1xZnfXt9N45mSUutwJ-6eApWFAUo-4eZB6Lg8BIGeuH3FhfUHSIgXqpkFBojDKvNwlQcY58wIrx-hsyM10Y4yGImm1tC-vE0qSvuDEFpwMBVuYDvBKVrD-h0zi2cP3zSd3BITQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia</title><source>Access via Wiley Online Library</source><creator>Valu dos Santos, Lorena Aline ; Burgos, Ivonne Carolina Bolaños ; Costa, Mônica Vieira ; de Oliveira Hansen, Erika ; Dias, Natália Silva ; da Fonseca, Aristeu Mascarenhas ; Miranda, Mariana Figueiredo ; Miranda, Millena Figueiredo ; Gomes, Giulia Costa ; de Mattos Viana, Bernardo ; Bicalho, Maria Aparecida Camargos</creator><creatorcontrib>Valu dos Santos, Lorena Aline ; Burgos, Ivonne Carolina Bolaños ; Costa, Mônica Vieira ; de Oliveira Hansen, Erika ; Dias, Natália Silva ; da Fonseca, Aristeu Mascarenhas ; Miranda, Mariana Figueiredo ; Miranda, Millena Figueiredo ; Gomes, Giulia Costa ; de Mattos Viana, Bernardo ; Bicalho, Maria Aparecida Camargos</creatorcontrib><description>Background
Comparison between functionality and cognition in elderly patients with Alzheimer’s dementia (AD) and without cognitive impairment with positive and negative Aβ‐42 and p‐Tau biomarkers evaluated using the Luminex technique.
Method
Patients with Alzheimer’s dementia and normal cognition (control) were recruited. They were divided in two groups according to their clinical diagnosis: AD group (n=30) and control group (CTRL) (n=10). The AD group was then divided in patients with positive (n=21) and negative (n=9) Aβ‐42 and p‐Tau biomarkers. The participants were submitted to sociodemographic. The general cognition was evaluated through the following instruments: the Mini‐Mental State Examination (MMSE), semantic verbal fluency (SVF), animal fluency, short term memory, and recognition of CERAD battery, and functionality was evaluated by the Pfeffer scale. Samples from the cerebrospinal fluid (CSF) of patients were collected, processed, and stored at ‐80°C until use. The Luminex technique was then used for the Aβ‐42, t‐Tau, p‐Tau, t‐Tau/Aβ‐42 ratio, and p‐Tau/Aβ‐42 ratio biomarker analysis. Obtained data was processed and analyzed through the software SPSS 22.0.
Result
Comparison between control patients and patients with AD, as defined by clinical diagnosis, did not show significant differences regarding to Aβ‐42 expression in CSF (U=91,000; p=0,067), (AD=1119,0360, SD=708,98952 vs CTRL=775,2623 SD=341,67835). However, there was a significant difference between groups concerning t‐Tau protein, (U=198,500; p=0,028), p‐Tau (U=250,00, p=0,001) and p‐Tau/Aβ‐42 ratio (U=238,00; p=0,005). In terms of cognitive variables, all showed significant differences between groups: MMSE (U=46,500, p=0,001), SVF (U=39,000; p<0,001), short term memory (U=27,000, p<0,001), recognition (U=72,500,p=0,014), as well as functionality (U=258,500, p<0,001). There was no difference regarding the age (U= 201,500; p=0,109) and formal education (U=201,500, p=0,109). As for the AD groups with positive and negative biomarkers, there was no significant difference in cognitive variables, age, formal education, and functionality.
Conclusion
AD group with negative biomarkers non differ in terms of cognition. Comparing the control and AD groups, there were differences in functionality, cognition, and biomarkers. However, comparing AD groups in terms of biomarkers, there was no difference in functionality performance, short‐term memory, fluency and general cognition. Therefore, the biomarkers do not indicate significant cognitive differences in the group of patients with dementia.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.057838</identifier><language>eng</language><ispartof>Alzheimer's & dementia, 2021-12, Vol.17 (S4), p.n/a</ispartof><rights>2021 the Alzheimer's Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Falz.057838$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Falz.057838$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Valu dos Santos, Lorena Aline</creatorcontrib><creatorcontrib>Burgos, Ivonne Carolina Bolaños</creatorcontrib><creatorcontrib>Costa, Mônica Vieira</creatorcontrib><creatorcontrib>de Oliveira Hansen, Erika</creatorcontrib><creatorcontrib>Dias, Natália Silva</creatorcontrib><creatorcontrib>da Fonseca, Aristeu Mascarenhas</creatorcontrib><creatorcontrib>Miranda, Mariana Figueiredo</creatorcontrib><creatorcontrib>Miranda, Millena Figueiredo</creatorcontrib><creatorcontrib>Gomes, Giulia Costa</creatorcontrib><creatorcontrib>de Mattos Viana, Bernardo</creatorcontrib><creatorcontrib>Bicalho, Maria Aparecida Camargos</creatorcontrib><title>The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia</title><title>Alzheimer's & dementia</title><description>Background
Comparison between functionality and cognition in elderly patients with Alzheimer’s dementia (AD) and without cognitive impairment with positive and negative Aβ‐42 and p‐Tau biomarkers evaluated using the Luminex technique.
Method
Patients with Alzheimer’s dementia and normal cognition (control) were recruited. They were divided in two groups according to their clinical diagnosis: AD group (n=30) and control group (CTRL) (n=10). The AD group was then divided in patients with positive (n=21) and negative (n=9) Aβ‐42 and p‐Tau biomarkers. The participants were submitted to sociodemographic. The general cognition was evaluated through the following instruments: the Mini‐Mental State Examination (MMSE), semantic verbal fluency (SVF), animal fluency, short term memory, and recognition of CERAD battery, and functionality was evaluated by the Pfeffer scale. Samples from the cerebrospinal fluid (CSF) of patients were collected, processed, and stored at ‐80°C until use. The Luminex technique was then used for the Aβ‐42, t‐Tau, p‐Tau, t‐Tau/Aβ‐42 ratio, and p‐Tau/Aβ‐42 ratio biomarker analysis. Obtained data was processed and analyzed through the software SPSS 22.0.
Result
Comparison between control patients and patients with AD, as defined by clinical diagnosis, did not show significant differences regarding to Aβ‐42 expression in CSF (U=91,000; p=0,067), (AD=1119,0360, SD=708,98952 vs CTRL=775,2623 SD=341,67835). However, there was a significant difference between groups concerning t‐Tau protein, (U=198,500; p=0,028), p‐Tau (U=250,00, p=0,001) and p‐Tau/Aβ‐42 ratio (U=238,00; p=0,005). In terms of cognitive variables, all showed significant differences between groups: MMSE (U=46,500, p=0,001), SVF (U=39,000; p<0,001), short term memory (U=27,000, p<0,001), recognition (U=72,500,p=0,014), as well as functionality (U=258,500, p<0,001). There was no difference regarding the age (U= 201,500; p=0,109) and formal education (U=201,500, p=0,109). As for the AD groups with positive and negative biomarkers, there was no significant difference in cognitive variables, age, formal education, and functionality.
Conclusion
AD group with negative biomarkers non differ in terms of cognition. Comparing the control and AD groups, there were differences in functionality, cognition, and biomarkers. However, comparing AD groups in terms of biomarkers, there was no difference in functionality performance, short‐term memory, fluency and general cognition. Therefore, the biomarkers do not indicate significant cognitive differences in the group of patients with dementia.</description><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1OwzAQhS0EEqWw4QReI1Js589ZRhV_UiU2ZcMmcpJJY0icyE6p2lWPwJYDcAEOwiF6EhwCiBWreZr3zZPmIXRKyYQSwi5EtZkQP-Qu30Mj6vvM8VkY7f_qgByiI2MeCfEIp_4Ivc1LwBoq0clGmVK2WNSNWuD44323ffEYFirHrZVzscSpbGqhn0Cbc1wsVdbfiEp26y8qaxZK9issFW5tIKjO4JXsymbZ_bjPgGXdCqlr6w7hf0kcV5sSZA16t301OIcek-IYHRSiMnDyPcfo_upyPr1xZnfXt9N45mSUutwJ-6eApWFAUo-4eZB6Lg8BIGeuH3FhfUHSIgXqpkFBojDKvNwlQcY58wIrx-hsyM10Y4yGImm1tC-vE0qSvuDEFpwMBVuYDvBKVrD-h0zi2cP3zSd3BITQ</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Valu dos Santos, Lorena Aline</creator><creator>Burgos, Ivonne Carolina Bolaños</creator><creator>Costa, Mônica Vieira</creator><creator>de Oliveira Hansen, Erika</creator><creator>Dias, Natália Silva</creator><creator>da Fonseca, Aristeu Mascarenhas</creator><creator>Miranda, Mariana Figueiredo</creator><creator>Miranda, Millena Figueiredo</creator><creator>Gomes, Giulia Costa</creator><creator>de Mattos Viana, Bernardo</creator><creator>Bicalho, Maria Aparecida Camargos</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202112</creationdate><title>The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia</title><author>Valu dos Santos, Lorena Aline ; Burgos, Ivonne Carolina Bolaños ; Costa, Mônica Vieira ; de Oliveira Hansen, Erika ; Dias, Natália Silva ; da Fonseca, Aristeu Mascarenhas ; Miranda, Mariana Figueiredo ; Miranda, Millena Figueiredo ; Gomes, Giulia Costa ; de Mattos Viana, Bernardo ; Bicalho, Maria Aparecida Camargos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1138-74081e2b760b403d6b4387eeed23598a740a0bfbe13b6f0979c4d306c882464d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valu dos Santos, Lorena Aline</creatorcontrib><creatorcontrib>Burgos, Ivonne Carolina Bolaños</creatorcontrib><creatorcontrib>Costa, Mônica Vieira</creatorcontrib><creatorcontrib>de Oliveira Hansen, Erika</creatorcontrib><creatorcontrib>Dias, Natália Silva</creatorcontrib><creatorcontrib>da Fonseca, Aristeu Mascarenhas</creatorcontrib><creatorcontrib>Miranda, Mariana Figueiredo</creatorcontrib><creatorcontrib>Miranda, Millena Figueiredo</creatorcontrib><creatorcontrib>Gomes, Giulia Costa</creatorcontrib><creatorcontrib>de Mattos Viana, Bernardo</creatorcontrib><creatorcontrib>Bicalho, Maria Aparecida Camargos</creatorcontrib><collection>CrossRef</collection><jtitle>Alzheimer's & dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valu dos Santos, Lorena Aline</au><au>Burgos, Ivonne Carolina Bolaños</au><au>Costa, Mônica Vieira</au><au>de Oliveira Hansen, Erika</au><au>Dias, Natália Silva</au><au>da Fonseca, Aristeu Mascarenhas</au><au>Miranda, Mariana Figueiredo</au><au>Miranda, Millena Figueiredo</au><au>Gomes, Giulia Costa</au><au>de Mattos Viana, Bernardo</au><au>Bicalho, Maria Aparecida Camargos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia</atitle><jtitle>Alzheimer's & dementia</jtitle><date>2021-12</date><risdate>2021</risdate><volume>17</volume><issue>S4</issue><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background
Comparison between functionality and cognition in elderly patients with Alzheimer’s dementia (AD) and without cognitive impairment with positive and negative Aβ‐42 and p‐Tau biomarkers evaluated using the Luminex technique.
Method
Patients with Alzheimer’s dementia and normal cognition (control) were recruited. They were divided in two groups according to their clinical diagnosis: AD group (n=30) and control group (CTRL) (n=10). The AD group was then divided in patients with positive (n=21) and negative (n=9) Aβ‐42 and p‐Tau biomarkers. The participants were submitted to sociodemographic. The general cognition was evaluated through the following instruments: the Mini‐Mental State Examination (MMSE), semantic verbal fluency (SVF), animal fluency, short term memory, and recognition of CERAD battery, and functionality was evaluated by the Pfeffer scale. Samples from the cerebrospinal fluid (CSF) of patients were collected, processed, and stored at ‐80°C until use. The Luminex technique was then used for the Aβ‐42, t‐Tau, p‐Tau, t‐Tau/Aβ‐42 ratio, and p‐Tau/Aβ‐42 ratio biomarker analysis. Obtained data was processed and analyzed through the software SPSS 22.0.
Result
Comparison between control patients and patients with AD, as defined by clinical diagnosis, did not show significant differences regarding to Aβ‐42 expression in CSF (U=91,000; p=0,067), (AD=1119,0360, SD=708,98952 vs CTRL=775,2623 SD=341,67835). However, there was a significant difference between groups concerning t‐Tau protein, (U=198,500; p=0,028), p‐Tau (U=250,00, p=0,001) and p‐Tau/Aβ‐42 ratio (U=238,00; p=0,005). In terms of cognitive variables, all showed significant differences between groups: MMSE (U=46,500, p=0,001), SVF (U=39,000; p<0,001), short term memory (U=27,000, p<0,001), recognition (U=72,500,p=0,014), as well as functionality (U=258,500, p<0,001). There was no difference regarding the age (U= 201,500; p=0,109) and formal education (U=201,500, p=0,109). As for the AD groups with positive and negative biomarkers, there was no significant difference in cognitive variables, age, formal education, and functionality.
Conclusion
AD group with negative biomarkers non differ in terms of cognition. Comparing the control and AD groups, there were differences in functionality, cognition, and biomarkers. However, comparing AD groups in terms of biomarkers, there was no difference in functionality performance, short‐term memory, fluency and general cognition. Therefore, the biomarkers do not indicate significant cognitive differences in the group of patients with dementia.</abstract><doi>10.1002/alz.057838</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-5260 |
| ispartof | Alzheimer's & dementia, 2021-12, Vol.17 (S4), p.n/a |
| issn | 1552-5260 1552-5279 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_alz_057838 |
| source | Access via Wiley Online Library |
| title | The relationship among Aβ‐42 and p‐Tau biomarkers, functionality and cognition in patients without cognitive impairment and patients with Alzheimer’s dementia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A49%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relationship%20among%20A%CE%B2%E2%80%9042%20and%20p%E2%80%90Tau%20biomarkers,%20functionality%20and%20cognition%20in%20patients%20without%20cognitive%20impairment%20and%20patients%20with%20Alzheimer%E2%80%99s%20dementia&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Valu%20dos%20Santos,%20Lorena%20Aline&rft.date=2021-12&rft.volume=17&rft.issue=S4&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.057838&rft_dat=%3Cwiley_cross%3EALZ057838%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |